



Supporting Information

for

Morpholine-mediated defluorinative cycloaddition of *gem*-difluoroalkenes and organic azides

Tzu-Yu Huang, Mario Djugovski, Sweta Adhikari, Destinee L. Manning
and Sudeshna Roy

Beilstein J. Org. Chem. **2023**, *19*, 1545–1554. [doi:10.3762/bjoc.19.111](https://doi.org/10.3762/bjoc.19.111)

General information, experimental procedures for all the substrates and intermediates, characterization data, and NMR spectra (^1H , ^{19}F , and ^{13}C NMR)

Table of contents

1. General information.....	S2
2. Azides safety.....	S2
3. Optimization studies:.....	S3
4. General procedure for synthesizing <i>gem</i> -difluoro olefins.....	S6
5. General procedure for the synthesis of organic azides.....	S8
Method A:.....	S8
Method B:.....	S8
6. General procedure for the synthesis of 1,4,5-trisubstituted-1,2,3-triazoles.....	S12
7. Time course study.....	S22
8. Mechanistic study.....	S23
9. Regioisomer study:.....	S26
10. Scale-up experiment:.....	S28
11. ¹ H, ¹⁹ F and, ¹³ C NMR spectra:.....	S29
12. References:.....	S46

1. General information

Unless otherwise noted, all reactions were carried out under argon atmosphere. All commercially available reagents were used without further purification. All of the solvents were treated according to known methods. For TLC, Sorbtech silica XG TLC plates w/UV254 indicator was used and visualized under a UV lamp. Flash column chromatography was performed in Biotage Isolera One with Biotage SNAP 10–50g cartridges. ^1H , ^{19}F , and ^{13}C NMR spectra were recorded on a Bruker Avance-500 (125 MHz) spectrometer and chemical shifts are reported in ppm (δ) using deuterated solvents for ^1H , ^{13}C NMR, and ^{19}F NMR. CDCl_3 ($\delta = 77.16$ ppm) for ^{13}C NMR, CFCl_3 ($\delta = 0$ ppm) for ^{19}F NMR, and CDCl_3 ($\delta = 7.26$ ppm) for ^1H NMR were used as internal standards. HRMS was recorded using quadrupole-TOF was used to obtain the data both in positive and negative modes. ATR-IR was taken using an Agilent Technologies Cary 600series FTIR Spectrometer. Melting point was recorded using the Stanford Research System OptiMelt Automated Melting Point System. Data were reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublets, td = triplet of doublets, qd = quartet of doublets, h = m = multiplet), coupling constants (Hz) and integration.


LiHMDS was acquired from Thermo Scientific Chemicals in a 100 mL glass container, appropriately labeled as lithium bis(trimethylsilyl)amide, 1 M solution in THF/ethylbenzene, AcroSeal™, Thermo Scientific Chemicals. Its corresponding catalog number: 347701000.

2. Azides safety

Caution must always be exercised when working with azides. It is important to ensure that the carbon-to-nitrogen ratio in organic azides remains above three. An alternative guideline known as the "rule of six" dictates that there should be a minimum of six carbon atoms per energetic functional group. Organic azides, especially those with low molecular weight or high nitrogen content, have the potential to be explosive. The application of heat, light, or pressure can trigger the decomposition of azides. Additionally, the azide ion is toxic, necessitating the use of gloves when handling sodium azide. When conducting experiments involving heating azides in the presence of copper, a blast shield should always be employed. It is crucial to never mix azides or their waste with acidic, metallic, or halogenated solvents.

3. Optimization studies:

Table S1. Optimization of reaction conditions^[a]



entry	R	Catalyst ^[c]	Base (equiv)	Solvent	T, °C	t, (h)	Yield % ^[d]
Molarity							
1	H ^[b]	-	K ₃ PO ₄ (2)	Morpholine (0.7 M)	110	48	39
2	H ^[b]	-	K ₃ PO ₄ (2)	Morpholine (0.5 M)	110	48	42
3	H ^[b]	-	K ₃ PO ₄ (2)	Morpholine (0.2 M)	110	48	30
Temperature							
4	CN	NiCl ₂ (dppp) ₂	K ₃ PO ₄ (2)	Morpholine (0.4 M)	100	24	36
5	CN	NiCl ₂ (dppp) ₂	K ₃ PO ₄ (2)	Morpholine (0.4 M)	75	24	44
6	CN	NiCl ₂ (dppp) ₂	K ₃ PO ₄ (2)	Morpholine (0.4 M)	50	24	35
7	CN	NiCl ₂ (dppp) ₂	LiHMDS (0.4)	Morpholine (0.4 M)	75	48	40
8	CN	NiCl ₂ (dppp) ₂	LiHMDS (0.4)	Morpholine (0.4 M)	25	48	0
9	CN	NiCl ₂ (dppp) ₂	LiHMDS (0.4)	Morpholine (0.4 M)	0	48	0
Base							
10	F	CuSO ₄ (1)	DIPEA (2)	Morpholine (0.4 M)	75	48	38 ^[e]
11	F	CuSO ₄ (1)	NaHMDS (2)	Morpholine (0.4 M)	75	48	24 ^[e]
Lithium Source							
12	CN	LiCl (0.1)	Cs ₂ CO ₃ (2)	Morpholine (0.4 M)	75	48	29
Solvent							
13	H ^[b]	-	K ₃ PO ₄ (2)	Morpholine (0.4 M), DMF (10 equiv)	110	48	35
14	H ^[b]	-	K ₃ PO ₄ (2)	Morpholine (10 equiv), DMF (250 equiv)	110	48	27
15	CN	-	K ₃ PO ₄ (2)	1,4-Dioxane (0.3 M)	95	48	0
16	CN	-	LiHMDS (0.4)	2-Pyrrolidinone (0.4 M)	75	48	0
17	CN	-	LiHMDS (0.4)	Morpholine (0.4 M), Toluene (20 equiv)	75	48	36
18	F	CuSO ₄ (1)	Cs ₂ CO ₃ (2)	Morpholine (20 equiv), DMF (0.4 M)	75	48	53 ^[e]
19	F	CuSO ₄ (1)	Cs ₂ CO ₃ (2)	Morpholine (10 equiv), DMF (0.4 M)	75	48	37 ^[e]

20	F	CuSO ₄ (1)	Cs ₂ CO ₃ (2)	Morpholine (5 equiv), DMF (0.4 M)	75	48	38 ^[e]
21	F	CuSO ₄ (1)	Cs ₂ CO ₃ (2)	Morpholine (2 equiv), DMF (0.4 M)	75	48	25 ^[e]
Microwave conditions							
22	CN	-	LiHMDS (0.4)	Morpholine (0.4 M)	135	1.5	15
Two-Portion Addition							
23 ^[f]	CN	-	LiHMDS (0.4)	Morpholine (0.4 M)	75	48	15
Scale up of reaction							
24	CN	-	LiHMDS (0.4)	Morpholine (0.4 M)	75	90	57

^[a]Standard reaction conditions: 1 equiv of *gem*-difluoroalkene **1** (0.14 mmol), 1.5 equiv of aryl azide **2a** and **2b** (0.21 mmol), and 0.3 mL morpholine (0.4 M) were mixed and heated at 110 °C. ^[b]2.0 Equiv of azide was used. ^[c]0.1 Equiv of catalyst used unless otherwise noted. ^[d]Isolated yield. ^[e]*para*-Fluorophenyl azide was used for screening to facilitate reaction monitoring via ¹⁹F NMR. Yield was obtained by utilizing the relative integration. ^[f]1.5 equiv of *gem*-difluoroalkene **1** (0.14 mmol), and 1equiv of aryl azide **2b** (0.21 mmol) were used. The 2,2-difluorovinylarene **1** was added in two portions with 0.75 equiv at t = 0 min and the remainder 0.75 equiv was added at t = 16 h.

^[e]The yield was obtained by utilizing the relative integration




Figure S1. The yield was obtained by utilizing the relative integration.

$$\text{Entry 18: } 1.00/1.00+1.35+0.32=37\%$$





Figure S2. The yield was obtained by utilizing the relative integration.


$$\text{Entry 19: } 1.00/1.00+1.43+0.16=38\%$$

4. General procedure for synthesizing *gem*-difluoro olefins



In an oven-dried, Ar-flushed vial charged with a stirring bar, sodium 2-chloro-2,2-difluoroacetate (6.0 mmol, 1.5 equiv) and triphenylphosphine (5.0 mmol, 1.2 equiv) were added. The vial was then vacuumed and flushed with Ar three times. Next, DMF (1.20 mL, 1.5 mL/mmol) was added and stirred until the reaction mixture became homogenous. Once mixed, the appropriate aldehyde (0.8 mmol, 1 equiv) was added and stirred at 100 °C under Ar. Caution when using balloons due to carbon dioxide evolution. The reaction mixture was stirred for 6 h or until completion (monitored by TLC or ^{19}F NMR spectroscopy) under the same conditions.

1-(2,2-Difluorovinyl)-4-methylbenzene (**1**)




1-(2,2-Difluorovinyl)-4-methylbenzene (1) was prepared following the general procedure using 4-methylbenzaldehyde (500 mg, 4.2 mmol), sodium 2-chloro-2,2-difluoroacetate (951 mg, 6.2 mmol) and triphenylphosphine (1.3 g, 5.0 mmol). The product was obtained in 65% yield (418 mg) as a colorless oil.

^1H NMR (400 MHz, Chloroform-*d*) δ 7.23 (d, $J = 8.2$ Hz, 2H), 7.15 (d, $J = 8.0$ Hz, 2H), 5.21 (d, $J = 3.9$ Hz, 1H), 2.34 (s, 3H).

^{19}F NMR (377 MHz, Chloroform-*d*) δ -83.69 (dd, $J = 33.8, 26.4$ Hz), -85.81 (dd, $J = 33.8, 3.8$ Hz).

Spectroscopic data for (**1**) are consistent with previously reported data for this compound [1].

1-(*tert*-Butyl)-4-(2,2-difluorovinyl)benzene (**1b**)




1-(*tert*-Butyl)-4-(2,2-difluorovinyl)benzene (1b) was prepared following the general procedure using benzaldehyde,4-(1,1-dimethylethyl) (250 mg, 1.5 mmol), sodium 2-chloro-2,2-difluoroacetate (352 mg, 2.3 mmol) and triphenylphosphine (485 mg, 1.8 mmol). The product was obtained in 75% yield (228 mg) as a reddish-brown oil.

^1H NMR (400 MHz, Chloroform-*d*) δ 7.44–7.25 (m, 4H), 5.28 (dd, $J = 26.5, 3.8$ Hz, 1H), 1.35 (s, 9H).

^{19}F NMR (376 MHz, Chloroform-*d*) δ -83.59 (dd, $J = 33.2, 26.3$ Hz), -85.54 (dd, $J = 33.4, 4.0$ Hz).

Spectroscopic data for (**1b**) are consistent with previously reported data for this compound [2].

1-(2,2-Difluorovinyl)-4-methoxybenzene (1c)




1-(2,2-Difluorovinyl)-4-methoxybenzene (1c) was prepared following the general procedure using 4-methoxybenzaldehyde (500 mg, 3.7 mmol), sodium 2-chloro-2,2-difluoroacetate (840 mg, 5.5 mmol) and triphenylphosphine (1.2 g, 4.4 mmol). The product was obtained in 80% yield (501 mg) as a colorless oil.

¹H NMR (400 MHz, Chloroform-*d*) δ 7.23 (d, $J = 8.2$ Hz, 2H), 7.15 (d, $J = 8.0$ Hz, 2H), 5.21 (d, $J = 3.9$ Hz, 1H), 2.34 (s, 3H).

¹⁹F NMR (376 MHz, Chloroform-*d*) δ -85.18 (dd, $J = 36.8, 26.5$ Hz), -86.98 (dd, $J = 36.8, 4.0$ Hz).

Spectroscopic data for **(1c)** are consistent with previously reported data for this compound [3].

1-(2,2-Difluoroethenyl)-4-benzonitrile (1d)




1-(2,2-Difluoroethenyl)-4-benzonitrile (1d) was prepared following the general procedure using 4-formylbenzonitrile (243 mg, 1.9 mmol), sodium 2-chloro-2,2-difluoroacetate (426mg, 2.8 mmol) and triphenylphosphine (586mg, 2.2 mmol). The product was obtained in 69% yield (212 mg) as a colorless oil.

¹H NMR (400 MHz, Chloroform-*d*) δ 7.62 (d, $J = 8.5$ Hz, 2H), 7.42 (d, $J = 8.5$ Hz, 2H), 5.34 (dd, $J = 25.5, 3.4$ Hz, 1H).

¹⁹F NMR (377 MHz, Chloroform-*d*) δ -78.32 (dd, $J = 25.4, 20.5$ Hz), -79.98 (dd, $J = 20.5, 3.4$ Hz).

Spectroscopic data for **(1e)** are consistent with previously reported data for this compound [4].

2-(2,2-Difluorovinyl)naphthalene (1e)



2-(2,2-Difluorovinyl)naphthalene (1e) was prepared following the general procedure using naphthalene-2-carbaldehyde (260 mg, 1.7 mmol), sodium 2-chloro-2,2-difluoroacetate (382 mg, 2.5 mmol) and triphenylphosphine (526 mg, 2.0 mmol). The product was obtained in 88% yield (278 mg) as a colorless oil.


¹H NMR (400 MHz, Chloroform-*d*) δ 7.84–7.73 (m, 4H), 7.52–7.42 (m, 3H), 5.44 (dd, $J = 26.2, 3.8$ Hz, 1H).

¹⁹F NMR (377 MHz, Chloroform-*d*) δ -82.44 (dd, $J = 30.7, 26.0$ Hz), -84.16 (dd, $J = 30.9, 3.8$ Hz).

Spectroscopic data for **(1e)** are consistent with previously reported data for this compound [4].

5. General procedure for the synthesis of organic azides


Method A:



The corresponding aniline (500 mg, 1 equiv) was suspended in methanol (4 mL) and water (3 mL). Then, HCl (2 mL) was added at 0 °C to the mixture which was stirred for another 5 minutes. The mixture was stirred at 0 °C for 20 minutes after which sodium nitrite (1.2 equiv) in water (1.5 mL) was added dropwise over 10 minutes. After a solution of sodium azide (1.2 equiv) in water (1.5 mL) was added dropwise to the reaction mixture for over 10 minutes, the reaction mixture was stirred at room temperature for 2 h or until completion (monitored by TLC) under the same conditions. The reaction was quenched with water and the organic layer was extracted with ethyl acetate ($\times 3$), dried with anhydrous Na₂SO₄, and concentrated using a rotavap. Unless other noted, the organic azides were used without further purification.


Warning: Working with azides demands caution due to potential explosiveness. This reaction can form hydrazoic acid which is highly explosive. Guidelines include a carbon-to-nitrogen ratio above three and the "rule of six," requiring six carbon atoms per energetic group. High-nitrogen organic azides are sensitive to heat, light, and pressure, possibly exploding. Sodium azide, with toxic azide ions, needs glove use. Copper-heated azides require a blast shield. Avoid mixing azides or waste with acidic, metallic, or halogenated solvents for safety. For more information, please see the warning on page 2 of the SI.

Method B:



The corresponding aniline (500 mg, 1 equiv) and sodium azide (1.2 equiv) were suspended in DMF (2 mL, 1 M) and the reaction mixture was stirred at 60 °C for 6 h or until completion (monitored by TLC). The reaction was quenched with brine and the organic layer was extracted with ethyl acetate ($\times 3$), dried with anhydrous Na₂SO₄, and concentrated in vacuo. The products were obtained after purification by column chromatography (gradient: 0–20% ethyl acetate in hexane) on silica gel.

4-Azidobenzonitrile (2)




4-Azidobenzonitrile (2) was prepared following method A using 4-aminobenzonitrile (500 mg, 4.2 mmol), sodium nitrite (350 mg, 5.0 mmol), and sodium azide (330 mg, 5.0 mmol). The product was obtained in 89% yield (546 mg) as a yellow solid.

¹H NMR (400 MHz, Chloroform-*d*) δ 7.70–7.63 (m, 2H), 7.16–7.09 (m, 2H).

Spectroscopic data for (2) is consistent with previously reported data for this compound [5].

3-Azidobenzonitrile (2a)




3-Azidobenzonitrile (2a) was prepared following method A using 3-aminobenzonitrile (257 mg, 2.1 mmol), sodium nitrite (180 mg, 2.6 mmol), and sodium azide (170 mg, 2.6 mmol). The product was obtained in 92% yield (287 mg) as a brown solid.

¹H NMR (400 MHz, Chloroform-*d*) δ 7.58 – 7.40 (m, 2H), 7.37 – 7.22 (m, 2H).

Spectroscopic data for **(2a)** is consistent with previously reported data for this compound [6].

1-Azido-3,5-dimethoxybenzene (2b)




1-Azido-3,5-dimethoxybenzene (2b) was prepared following method A using 3,5-dimethoxyaniline (250 mg, 1.6 mmol), sodium nitrite (135 mg, 2.0 mmol), and sodium azide (127 mg, 2.0 mmol). The product was obtained in 86% yield (250 mg) as a brown solid after extraction.

¹H NMR (400 MHz, Chloroform-*d*) δ 6.22 (dd, $J = 22.9, 2.2$ Hz, 3H), 3.78 (s, 6H).

Spectroscopic data for **(2b)** is consistent with previously reported data for this compound [7].

1-Azido-3-fluorobenzene (2c)




1-Azido-3-fluorobenzene (2c) was prepared following method A using 3-fluoroaniline (250 mg, 2.3 mmol), sodium nitrite (193 mg, 2.8 mmol), and sodium azide (182 mg, 2.8 mmol). The product was obtained in 41% yield (128 mg) as a yellow liquid after extraction.

¹H NMR (400 MHz, Chloroform-*d*) δ 7.31 (td, $J = 8.2, 6.2$ Hz, 1H), 6.89–6.81 (m, 2H), 6.74 (dt, $J = 9.6, 2.3$ Hz, 1H).

¹⁹F NMR (376 MHz, Chloroform-*d*) δ -111.36 (m).

Spectroscopic data for **(2c)** is consistent with previously reported data for this compound [8].


1-Azido-4-chlorobenzene (2d)



1-Azido-4-chlorobenzene (2d) was prepared following method A using 4-chloroaniline (250 mg, 1.9 mmol), sodium nitrite (162 mg, 2.3 mmol), and sodium azide (152 mg, 2.3 mmol). The product was obtained in 70% yield (210 mg) as a yellow solid.

$^1\text{H NMR}$ (400 MHz, Chloroform-*d*) δ 7.34–7.29 (m, 2H), 6.98–6.93 (m, 2H). Spectroscopic data for (**2d**) is consistent with previously reported data for this compound [8].

1-Azido-4-fluorobenzene (**2e**)




1-Azido-4-fluorobenzene (2e) was prepared following method A using 4-fluoroaniline (250 mg, 2.3 mmol), sodium nitrite (186 mg, 2.7 mmol), and sodium azide (176 mg, 2.7 mmol). The product was obtained in 77% yield (237 mg) as a solid.

$^1\text{H NMR}$ (400 MHz, Chloroform-*d*) δ 7.09–7.02 (m, 2H), 7.02–6.96 (m, 2H).

$^{19}\text{F NMR}$ (376 MHz, Chloroform-*d*) δ -118.26 (tt, $J = 8.2, 4.5$ Hz).

Spectroscopic data for (**2e**) is consistent with previously reported data for this compound [8].

5-Azido-1,2,3-trimethoxybenzene (**2f**)




5-Azido-1,2,3-trimethoxybenzene (2f) was prepared following method A using 3,4,5-trimethoxyaniline (260 mg, 1.4 mmol), sodium nitrite (117 mg, 1.7 mmol), and sodium azide (111 mg, 1.7 mmol). The product was obtained in 84% yield (249 mg) as a gray solid.

$^1\text{H NMR}$ (400 MHz, Chloroform-*d*) δ 6.25 (s, 2H), 3.85 (d, $J = 0.5$ Hz, 6H), 3.81 (d, $J = 0.6$ Hz, 3H).

Spectroscopic data for (**2f**) is consistent with previously reported data for this compound [7].

4-Azido-1,1'-biphenyl (2g)




4-Azido-1,1'-biphenyl (2g) was prepared following method A using [1,1'-biphenyl]-4-amine (200 mg, 1.2 mmol), sodium nitrite (98 mg, 1.4 mmol), and sodium azide (92 mg, 1.4 mmol). The product was obtained in 87% yield (202 mg) as a brown solid.

¹H NMR (400 MHz, Chloroform-*d*) δ 7.61–7.54 (m, 4H), 7.44 (ddd, $J = 7.8, 6.9, 1.2$ Hz, 2H), 7.38–7.32 (m, 1H), 7.13–7.08 (m, 2H).

Spectroscopic data for **(2g)** is consistent with previously reported data for this compound.[9]

1-(Azidomethyl)-3-(trifluoromethyl)benzene (2h)




1-(Azidomethyl)-3-(trifluoromethyl)benzene (2h) was prepared following method B using 1-(bromomethyl)-3-(trifluoromethyl)benzene (671 mg, 2.8 mmol) and sodium azide (219 mg, 3.4 mmol). The product was obtained in 23% yield (131 mg) as a clear liquid after column chromatography.

¹H NMR (400 MHz, Chloroform-*d*) δ 7.6–7.6 (m, 2H), 7.6–7.5 (m, 2H), 4.4 (s, 2H).

¹⁹F NMR (377 MHz, Chloroform-*d*) δ -63.25.


Spectroscopic data for **(2h)** is consistent with previously reported data for this compound [6].

6. General procedure for the synthesis of 1,4,5-trisubstituted-1,2,3-triazoles



In an oven-dried, Ar-flushed vial with a stirring bar, a solution of the corresponding *gem*-difluoroalkenes (20 mg, 1 equiv) and organic azides (31 mg, 1.5 equiv) were dissolved in morpholine (0.2 mL, 0.4 M). The solution was stirred for 10 minutes at room temperature under Ar. Then, lithium bis(trimethylsilyl)amide solution (54 μL , 1 M, 0.4 equiv) was added to the reaction mixture and it was purged with Ar three times. The reaction mixture was stirred at 75 $^\circ\text{C}$ for 48 h or until completion (monitored by TLC) under the same conditions. Upon completion, brine was added and the organic layer was extracted with ethyl acetate ($\times 3$), dried with anhydrous Na_2SO_4 , and concentrated *in vacuo*. 4-(5-Morpholino-4-(*p*-tolyl)-1*H*-1,2,3-triazol-1-yl)benzotrile was obtained after purification by column chromatography (gradient: 0–30% ethyl acetate in hexane) on silica gel.

4-(4-Morpholino-5-(*p*-tolyl)-1*H*-1,2,3-triazol-1-yl)benzotrile (3a)



4-(4-Morpholino-5-(*p*-tolyl)-1*H*-1,2,3-triazol-1-yl)benzotrile (3a) was obtained by using 1-(2,2-difluorovinyl)-4-methylbenzene (21 mg, 0.1 mmol), 4-azidobenzotrile (29 mg, 0.2 mmol) and lithium bis(trimethylsilyl)amide solution (54 μL , 1 M, 0.4 equiv) to obtain product in 70% yield (47 mg) as a light-yellow solid.

m.p. 223–225 $^\circ\text{C}$


$^1\text{H NMR}$ (400 MHz, Chloroform-*d*) δ 8.00 (d, $J = 8.2$ Hz, 2H), 7.85 (d, $J = 8.2$ Hz, 2H), 7.50 (d, $J = 7.6$ Hz, 2H), 7.27 (d, $J = 8.2$ Hz, 2H), 3.66 (t, $J = 4.7$ Hz, 4H), 2.93 (t, $J = 4.6$ Hz, 4H), 2.42 (s, 3H).

$^{13}\text{C NMR}$ (126 MHz, Chloroform-*d*) δ 141.5, 139.9, 139.4, 138.5, 133.3, 129.1, 129.0, 127.6, 124.4, 117.7, 112.8, 66.7, 50.6, 21.3.

HRMS: $\text{C}_{20}\text{H}_{19}\text{N}_5\text{O}$ [$\text{M} + \text{H}$] $^+$; calculated 346.1668, found 346.1695.

IR (ν , cm^{-1}): 2233.05, 2252.44, 2856.26, 2924.22.

4-(5-(4-(*tert*-Butyl)phenyl)-4-morpholino-1*H*-1,2,3-triazol-1-yl)benzonitrile (3b)



4-(5-(4-(*tert*-Butyl)phenyl)-4-morpholino-1*H*-1,2,3-triazol-1-yl)benzonitrile (3b) was obtained by using 1-(*tert*-butyl)-4-(2,2-difluorovinyl)benzene (23 mg, 0.1 mmol), 4-azidobenzonitrile (25 mg, 0.2 mmol) and lithium bis(trimethylsilyl)amide solution (47 μ L, 1 M, 0.4 equiv) to obtain product in 40% yield (18 mg) as a light-yellow solid.

m.p. 189–191 $^{\circ}$ C


1 H NMR (400 MHz, Chloroform-*d*) δ 8.01 (d, J = 8.9 Hz, 2H), 7.89–7.85 (m, 2H), 7.56 (d, J = 8.6 Hz, 2H), 7.49 (d, J = 8.7 Hz, 2H), 3.72–3.65 (m, 4H), 2.99–2.91 (m, 4H), 1.37 (s, 9H).

13 C NMR (126 MHz, Chloroform-*d*) δ 151.7, 141.5, 140.0, 133.3, 128.8, 127.6, 125.4, 124.4, 117.8, 112.8, 66.7, 50.7, 34.7, 31.3.

HRMS: C₂₃H₂₅N₅O [M + H]⁺; calculated 388.2137, found 388.2136.

IR (ν , cm⁻¹): 2212.76, 2229.84, 2856.49, 2975.06, 3065.69, 3102.93.

4-(5-(4-Methoxyphenyl)-4-morpholino-1*H*-1,2,3-triazol-1-yl)benzonitrile (3c)



4-(5-(4-Methoxyphenyl)-4-morpholino-1*H*-1,2,3-triazol-1-yl)benzonitrile (3c) was obtained by using 1-(2,2-difluorovinyl)-4-methoxybenzene (23 mg, 0.1 mmol), 4-azidobenzonitrile (29 mg, 0.2 mmol) and lithium bis(trimethylsilyl)amide solution (55 μ L, 1 M, 0.4 equiv) to obtain product in 51% yield (24 mg) as a light-yellow solid.

m.p. 192–194 $^{\circ}$ C


1 H NMR (400 MHz, Chloroform-*d*) δ 8.00 (d, J = 8.7 Hz, 2H), 7.86 (d, J = 8.7 Hz, 2H), 7.54 (d, J = 8.8 Hz, 2H), 7.00 (d, J = 8.8 Hz, 2H), 3.87 (s, 3H), 3.69–3.63 (m, 4H), 2.95–2.89 (m, 4H).

13 C NMR (126 MHz, Chloroform-*d*) δ 159.9, 141.3, 139.9, 139.2, 133.3, 130.4, 124.4, 122.9, 117.8, 113.8, 112.7, 66.7, 55.3, 50.7.

HRMS: C₂₀H₁₉N₅O₂ [M + H]⁺; calculated 362.1617, found 362.1638.

IR (ν , cm⁻¹): 2226.45, 2850.60, 2918.34, 3081.67, 3107.08.

4,4'-(4-Morpholino-1*H*-1,2,3-triazole-1,5-diyl)dibenzonitrile (3d)



4,4'-(4-Morpholino-1*H*-1,2,3-triazole-1,5-diyl)dibenzonitrile (3d) was obtained by using 4-(2,2-difluorovinyl)benzonitrile (22 mg, 0.1 mmol), 4-azidobenzonitrile (29 mg, 0.2 mmol) and lithium bis(trimethylsilyl)amide solution (55 μ L, 1 M, 0.4 equiv) to obtain product in 52% yield (25 mg) as a light-yellow solid.

mp 258–260 °C


¹H NMR (400 MHz, Chloroform-*d*) δ 7.95–7.87 (m, 4H), 7.84 (d, *J* = 8.5 Hz, 2H), 7.77 (d, *J* = 8.4 Hz, 2H), 3.74–3.65 (m, 4H), 2.98–2.90 (m, 4H).

¹³C NMR (126 MHz, Chloroform-*d*) δ 142.4, 139.6, 137.0, 135.2, 133.5, 132.3, 128.9, 125.0, 118.5, 117.5, 113.5, 112.1, 66.6, 50.5.

HRMS: C₂₀H₁₆N₅O [M + H]⁺; calculated 358.1492, found 358.1514.

IR (ν , cm⁻¹): 2226.03, 2826.06, 2849.85, 2859.46, 2893.69, 2915.39, 2961.13, 3063.93, 3082.86, 3100.77.

4-(4-Morpholino-5-(naphthalen-2-yl)-1*H*-1,2,3-triazol-1-yl)benzonitrile (3e)



4-(4-Morpholino-5-(naphthalen-2-yl)-1*H*-1,2,3-triazol-1-yl)benzonitrile (3e) was obtained by using 2-(2,2-difluorovinyl)naphthalene (22 mg, 0.1 mmol), 4-azidobenzonitrile (25 mg, 0.2 mmol) and lithium bis(trimethylsilyl)amide solution (46 μ L, 1 M, 0.4 equiv) to obtain product in 57% yield (25 mg) as a light-yellow solid.

m.p. 187–189 °C


¹H NMR (400 MHz, Chloroform-*d*) δ 8.12 (s, 1H), 8.04–7.99 (m, 2H), 7.97–7.87 (m, 5H), 7.76 (dd, *J* = 8.5, 1.7 Hz, 1H), 7.58–7.53 (m, 2H), 3.72–3.65 (m, 4H), 3.03–2.93 (m, 4H).

¹³C NMR (126 MHz, Chloroform-*d*) δ 141.9, 139.9, 139.2, 133.4, 133.1, 133.0, 128.2, 128.1, 127.9, 127.8, 126.7, 126.6, 124.6, 117.7, 113.0, 66.7, 50.7, 29.7.

HRMS: C₂₃H₁₉N₅O₂ [M + H]⁺; calculated 382.1668, found 382.1694.

IR (ν , cm⁻¹): 2227.07, 2849.88, 2955.68, 3051.53, 3068.40, 3101.40.

3-(4-Morpholino-5-(*p*-tolyl)-1*H*-1,2,3-triazol-1-yl)benzotrile (4a)



3-(4-Morpholino-5-(*p*-tolyl)-1*H*-1,2,3-triazol-1-yl)benzotrile (4a) was obtained by using 1-(2,2-difluorovinyl)-4-methylbenzene (24 mg, 0.16 mmol), 3-azidobenzotrile (22 mg, 0.16 mmol) and lithium bis(trimethylsilyl)amide solution (52 μ L, 1 M, 0.4 equiv) to obtain product in 41% yield (22 mg) as a white solid.

m.p. 169–171 $^{\circ}$ C


1 H NMR (400 MHz, Chloroform-*d*) δ 8.16 (t, J = 1.8 Hz, 1H), 8.07 (ddd, J = 8.2, 2.1, 1.2 Hz, 1H), 7.79 (dt, J = 7.8, 1.4 Hz, 1H), 7.70 (t, J = 8.0 Hz, 1H), 7.54–7.49 (m, 2H), 7.28 (d, J = 7.8 Hz, 2H), 3.68–3.65 (m, 4H), 2.96–2.91 (m, 4H), 2.43 (s, 3H).

13 C NMR (126 MHz, Chloroform-*d*) δ 141.4, 139.4, 138.5, 137.3, 132.4, 130.4, 129.2, 129.0, 128.4, 127.7, 127.4, 117.4, 113.7, 66.7, 50.7, 21.3.

HRMS: C₂₀H₁₉N₅O [M + H]⁺; calculated 346.1668, found 346.1695.

IR (ν , cm⁻¹): 2235.21, 2850.16, 2896.13, 2912.38, 2953.92.

4-(1-(3,5-Dimethoxyphenyl)-5-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)morpholine (4b)



4-(1-(3,5-Dimethoxyphenyl)-5-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)morpholine (4b) was obtained by using 1-(2,2-difluorovinyl)-4-methylbenzene (22 mg, 0.14 mmol), 1-azido-3,5-dimethoxybenzene (38 mg, 0.21 mmol) and lithium bis(trimethylsilyl)amide solution (52 μ L, 1 M, 0.4 equiv) to obtain product in 58% yield (31 mg) as a reddish-brown solid.

m.p. 127–129 $^{\circ}$ C


1 H NMR (400 MHz, Chloroform-*d*) δ 7.64–7.55 (m, 2H), 7.26 (d, J = 7.9 Hz, 2H), 6.86 (d, J = 2.3 Hz, 2H), 6.57 (t, J = 2.3 Hz, 1H), 3.85 (s, 6H), 3.70–3.62 (m, 4H), 2.96–2.90 (m, 4H), 2.41 (s, 3H).

13 C NMR (126 MHz, Chloroform-*d*) δ 161.1, 141.3, 138.0, 129.0, 128.5, 128.1, 126.7, 129.3, 103.2, 101.3, 66.9, 55.7, 50.4, 21.3.

HRMS: C₂₁H₂₄N₄O₃ [M + H]⁺; calculated 381.1927, found 381.1941.

IR (ν , cm⁻¹): 1711.69, 2849.71, 2920.62, 2952.92.

4-(1-(3-Fluorophenyl)-5-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)morpholine (4c)



4-(1-(3-Fluorophenyl)-5-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)morpholine (4c) was obtained by using 1-(2,2-difluorovinyl)-4-methylbenzene (40 mg, 0.26 mmol), 1-azido-3-fluorobenzene (53 mg, 0.39 mmol) and lithium bis(trimethylsilyl)amide solution (104 μ L, 1 M, 0.4 equiv) was used to obtain product in 50% yield (44 mg) as a light-yellow solid.

m.p. 164–166 °C

$^1\text{H NMR}$ (400 MHz, Chloroform-*d*) δ 7.59–7.49 (m, 5H), 7.26 (d, $J = 7.9$ Hz, 2H), 7.24–7.18 (m, 1H), 3.70–3.61 (m, 4H), 2.97–2.88 (m, 4H), 2.41 (s, 3H).


$^{13}\text{C NMR}$ (126 MHz, Chloroform-*d*) δ 162.6 (d, $J = 248.6$ Hz), 141.3, 138.7, 138.2, 137.7 (d, $J = 10.1$ Hz), 130.6 (d, $J = 8.9$ Hz), 129.0, 128.7, 127.9, 120.2 (d, $J = 3.3$ Hz), 116.2 (d, $J = 21.1$ Hz), 112.1 (d, $J = 25.1$ Hz), 66.7, 50.5, 21.3.

$^{19}\text{F NMR}$ (376 MHz, Chloroform-*d*) δ -110.80 (td, $J = 8.8, 5.6$ Hz).

HRMS: $\text{C}_{19}\text{H}_{19}\text{FN}_4\text{O}$ [$\text{M} + \text{H}$] $^+$; calculated 339.1621, found 339.1625.

IR (ν , cm^{-1}): 2849.54, 2894.32, 2916.11, 2950.74, 2965.75.

4-(1-(4-Chlorophenyl)-5-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)morpholine (4d)



4-(1-(4-Chlorophenyl)-5-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)morpholine (4d) was obtained by using 1-(2,2-difluorovinyl)-4-methylbenzene (20 mg, 0.14 mmol), 1-azido-4-chlorobenzene and sodium (30 mg, 0.20 mmol) and lithium bis(trimethylsilyl)amide solution (52 μ L, 1 M, 0.4 equiv) to obtain product in 39% yield (18 mg) as a light-yellow solid.

m.p. 205–207 °C


$^1\text{H NMR}$ (400 MHz, Methanol-*d*₄) δ 7.82–7.76 (m, 2H), 7.72–7.66 (m, 2H), 7.57 (d, $J = 8.0$ Hz, 2H), 7.36 (d, $J = 7.7$ Hz, 2H), 3.68–3.59 (m, 4H), 2.98–2.89 (m, 4H), 2.45 (s, 3H).

$^{13}\text{C NMR}$ (126 MHz, Chloroform-*d*) δ 141.4, 138.7, 138.2, 135.2, 135.1, 129.5, 129.1, 128.7, 128.0, 125.9, 66.8, 50.5, 21.3.

HRMS: $\text{C}_{19}\text{H}_{19}\text{ClN}_4\text{O}$ [$\text{M} + \text{H}$] $^+$; calculated 355.1326, found 355.1330.

IR (ν , cm^{-1}): 2851.68, 2886.79, 2941.53, 2963.04.

4-(1-(4-Fluorophenyl)-5-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)morpholine (4e)



4-(1-(4-Fluorophenyl)-5-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)morpholine (4e) was obtained by using 1-(2,2-difluorovinyl)-4-methylbenzene (40 mg, 0.26 mmol), 1-azido-4-fluorobenzene (53 mg, 0.39 mmol), and lithium bis(trimethylsilyl)amide solution (105 μ L, 1 M, 0.4 equiv) to obtain product in 22% yield (19 mg) as a light-yellow solid.

4-(1-(4-Fluorophenyl)-5-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)morpholine (4e) was obtained by using 1-(2,2-difluorovinyl)-4-methylbenzene (23 mg, 0.14 mmol), 1-azido-4-fluorobenzene (30 mg, 0.22 mmol), copper(II) sulfate anhydrous (23 mg, 0.14 mmol) and lithium bis(trimethylsilyl)amide solution (105 μ L, 1 M, 0.4 equiv) to obtain product in 56% yield (28 mg) as a light-yellow solid.

m.p. 177–179 $^{\circ}$ C

$^1\text{H NMR}$ (400 MHz, Chloroform-*d*) δ 7.72–7.65 (m, 2H), 7.62–7.56 (m, 2H), 7.30–7.20 (m, 4H), 3.68–3.59 (m, 4H), 2.94–2.86 (m, 4H), 2.41 (s, 3H).


$^{19}\text{F NMR}$ (376 MHz, Chloroform-*d*) δ -111.55 (ddd, $J = 12.9, 8.2, 4.7$ Hz).

$^{13}\text{C NMR}$ (126 MHz, Chloroform-*d*) δ 162.7 (d, $J = 250.2$ Hz), 141.4, 138.5, 138.1, 132.7 (d, $J = 3.2$ Hz), 129.1, 128.5, 128.0, 126.8 (d, $J = 8.7$ Hz), 116.3 (d, $J = 23.2$ Hz), 66.8, 50.5, 21.3.

HRMS: $\text{C}_{19}\text{H}_{19}\text{FN}_4\text{O}$ [$\text{M} + \text{H}$] $^{+}$; calculated 339.1621, found 339.1651.

IR (ν , cm^{-1}): 2332.47, 2360.85, 2848.90, 2890.26, 2912.21, 2946.79, 3075.27.

4-(5-(*p*-Tolyl)-1-(3,4,5-trimethoxyphenyl)-1*H*-1,2,3-triazol-4-yl)morpholine (4f)



4-(5-(*p*-Tolyl)-1-(3,4,5-trimethoxyphenyl)-1*H*-1,2,3-triazol-4-yl)morpholine (4f) was obtained by using 1-(2,2-difluorovinyl)-4-methylbenzene (22 mg, 0.14 mmol), 5-azido-1,2,3-trimethoxybenzene (29 mg, 0.14 mmol) and lithium bis(trimethylsilyl)amide solution (52 μ L, 1 M, 0.4 equiv) to obtain product in 36% yield (21 mg) as yellowish-brown solid.

m.p. 150–152 °C


¹H NMR (400 MHz, Chloroform-*d*) δ 7.63–7.57 (m, 2H), 7.31–7.22 (m, 2H), 6.93 (s, 2H), 3.92 (s, 9H), 3.70–3.61 (m, 4H), 2.97–2.90 (m, 4H), 2.41 (s, 3H).

¹³C NMR (126 MHz, Chloroform-*d*) δ 153.5, 141.3, 138.6, 138.1, 138.0, 132.2, 129.1, 128.5, 128.2, 102.6, 67.0, 61.1, 56.4, 50.4, 21.3.

HRMS: C₂₁H₂₄N₄O₃ [M + H]⁺; calculated 411.2032, found 411.2045.

IR (ν , cm⁻¹): 2847.85, 2918.43, 2949.23, 3002.17.

4-(1-([1,1'-Biphenyl]-4-yl)-5-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)morpholine (4g)



4-(1-([1,1'-Biphenyl]-4-yl)-5-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)morpholine (4g) was obtained by using 1-(2,2-difluorovinyl)-4-methylbenzene (20 mg, 0.13 mmol), 4-azido-1,1'-biphenyl (38 mg, 0.19 mmol) and lithium bis(trimethylsilyl)amide solution (52 μ L, 1 M, 0.4 equiv) to obtain product in 31% yield (12 mg) as a light-yellow solid.

m.p. 202-204 °C


¹H NMR (400 MHz, Chloroform-*d*) δ 7.78 (s, 4H), 7.68–7.61 (m, 4H), 7.53–7.47 (m, 2H), 7.43 (dd, J = 6.9, 1.8 Hz, 1H), 7.28 (d, J = 7.9 Hz, 2H), 3.70–3.65 (m, 4H), 2.99–2.94 (m, 4H), 2.42 (s, 3H).

¹³C NMR (126 MHz, Chloroform-*d*) δ 142.2, 141.4, 139.7, 138.5, 138.0, 135.7, 129.1, 129.0, 128.5, 128.2, 128.0, 127.9, 127.2, 125.1, 66.9, 50.5, 21.3.

HRMS: C₂₅H₂₄N₄O [M + H]⁺; calculated 397.2029, found 397.2039

IR (ν , cm⁻¹): 2349.28, 2846.10, 2920.73, 3288.72

4-(5-(*p*-Tolyl)-1-(3-(trifluoromethyl)benzyl)-1*H*-1,2,3-triazol-4-yl)morpholine (4h)



4-(5-(*p*-Tolyl)-1-(3-(trifluoromethyl)benzyl)-1*H*-1,2,3-triazol-4-yl)morpholine (4h) was obtained by using 1-(2,2-difluorovinyl)-4-methylbenzene (21 mg, 0.14 mmol), 1-(azidomethyl)-3-(trifluoromethyl)benzene (42 mg, 0.21 mmol) and lithium bis(trimethylsilyl)amide solution (56 μ L, 1 M, 0.4 equiv) at 110 °C for 72h to obtain product in 44% yield (25 mg) as a clear sticky liquid.

$^1\text{H NMR}$ (400 MHz, Chloroform-*d*) δ 7.63–7.57 (m, 2H), 7.55–7.47 (m, 4H), 7.24 (d, $J = 7.9$ Hz, 2H), 5.53 (s, 2H), 3.71–3.63 (m, 4H), 2.86–2.79 (m, 4H), 2.39 (s, 3H).


$^{19}\text{F NMR}$ (376 MHz, Chloroform-*d*) δ -63.24.

$^{13}\text{C NMR}$ (126 MHz, Chloroform-*d*) δ 140.9, 140.7, 138.2, 136.7, 131.3 (q, $J = 32.8$ Hz), 130.9, 129.6, 129.1, 128.6, 128.0, 125.2 (q, $J = 3.7$ Hz), 124.4 (q, $J = 3.7$ Hz), 123.7 (q, $J = 272.3$ Hz), 67.0, 50.9, 50.3, 21.3.

HRMS: $\text{C}_{21}\text{H}_{21}\text{F}_3\text{N}_4\text{O}$ [$\text{M} + \text{H}$] $^+$; calculated 403.1746, found 403.1750.

IR (ν , cm^{-1}): 1720.11, 2855.35, 2920.86, 2958.44.

4-(4-(Piperidin-1-yl)-5-(*p*-tolyl)-1*H*-1,2,3-triazol-1-yl)benzotrile (5a)



4-(4-(Piperidin-1-yl)-5-(*p*-tolyl)-1*H*-1,2,3-triazol-1-yl)benzotrile (5a) was obtained by using 1-(2,2-difluorovinyl)-4-methylbenzene 1-(2,2-difluorovinyl)-4-methylbenzene (22.33 mg, 1 equiv, 144.8 μ mol) and 4-azidobenzotrile (31.32 mg, 1.5 equiv, 217.3 μ mol) dissolved in piperidine (0.32 mL, 0.38 M). The reaction mixture ran with Ar and stirred for 10 minutes at room temperature. Then, lithium bis(trimethylsilyl)amide solution (57.94 μ L, 1 molar, 0.4 equiv) was added to the mixture and it was purged with Ar ($\times 3$). Then, the mixture was heated to

75 °C and stirred for 48 h to obtain the product with 42% yield (21 mg) as white solid after purification by column chromatography.

m.p. 175–177 °C


¹H NMR (400 MHz, Chloroform-*d*) δ 8.01 (d, *J* = 8.8 Hz, 2H), 7.84 (d, *J* = 8.8 Hz, 2H), 7.50 (d, *J* = 8.1 Hz, 2H), 7.29 – 7.27 (m, 1H), 7.25 (d, *J* = 1.1 Hz, 1H), 2.86 (s, 4H), 2.42 (s, 3H), 1.53 (s, 6H).

¹³C NMR (126 MHz, Chloroform-*d*) δ 142.9, 140.3, 139.0, 138.1, 133.2, 129.0, 128.9, 128.2, 124.2, 118.0, 112.4, 51.9, 25.8, 23.5, 21.3.

HRMS: C₂₁H₂₁N₅ [M + H]⁺; calculated 344.1875, found 344.1858

IR (ν, cm⁻¹): 1693.13, 2229.17, 2853.22, 2924.54

4-(4-(Azepan-1-yl)-5-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)benzonitrile (5b)



4-(4-(Azepan-1-yl)-5-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)benzonitrile (5b) was obtained by using 1-(2,2-difluorovinyl)-4-methylbenzene (20.54 mg, 1 equiv, 133.2 μmol) and 4-azidobenzonitrile (28.81 mg, 1.5 equiv, 199.9 μmol) dissolved in hexamethyleneimine (0.300 mL, 0.4 M). The reaction mixture was run with Ar and stirred for 10 minutes at room temperature. Then, lithium bis(trimethylsilyl)amide solution (53.30 μL, 1 molar, 0.4 equiv) was added to the mixture and it was purged with Ar (× 3). Then, the mixture was heated to 75 °C and stirred for 48 h to obtain the product with 30% yield (14.2 mg) as white solid after purification by column chromatography.

m.p. 158–160 °C

¹H NMR (400 MHz, Chloroform-*d*) δ 7.92 – 7.82 (m, 4H), 7.59 – 7.55 (m, 2H), 7.27 (d, *J* = 7.6 Hz, 2H), 3.13 – 3.00 (m, 4H), 2.41 (s, 3H), 1.6 (s, 8H).

¹³C NMR (126 MHz, Chloroform-*d*) δ 143.9, 140.1, 138.9, 138.1, 133.2, 129.2, 128.0, 127.9, 125.1, 118.0, 112.7, 54.1, 29.5, 27.7, 21.4.


HRMS: C₂₂H₂₃N₅ [M + H]⁺; calculated 358.2032, found 358.2007

IR (ν, cm⁻¹): 2218.62, 2877.88, 2950.55, 3030.90.

Table S2: Difference between the calculated and the observed HRMS data.

No.	MF[M + H] ⁺	Calculated	Found	Difference
3a	C ₂₀ H ₁₉ N ₅ O	346.1668	346.1695	0.0027
3b	C ₂₃ H ₂₅ N ₅ O	388.2137	388.2136	0.0001
3c	C ₂₀ H ₁₉ N ₅ O ₂	362.1617	362.1638	0.0021
3d	C ₂₀ H ₁₆ N ₅ O	358.1492	358.1514	0.0022
3e	C ₂₃ H ₁₉ N ₅ O ₂	382.1668	382.1694	0.0026
4a	C ₂₀ H ₁₉ N ₅ O	346.1668	346.1695	0.0027
4b	C ₂₁ H ₂₄ N ₄ O ₃	381.1927	381.1941	0.0014
4c	C ₁₉ H ₁₉ FN ₄ O	339.1621	339.1625	0.0004
4d	C ₁₉ H ₁₉ ClN ₄ O	355.1326	355.1330	0.0004
4e	C ₁₉ H ₁₉ FN ₄ O	339.1621	339.1651	0.0030
4f	C ₂₁ H ₂₄ N ₄ O ₃	411.2032	411.2045	0.0013
4g	C ₂₅ H ₂₄ N ₄ O	397.2029	397.2039	0.0010
4h	C ₂₁ H ₂₁ F ₃ N ₄ O	403.1746	403.1750	0.0004
5a	C ₂₁ H ₂₁ N ₅	344.1875	344.1858	0.0017
5b	C ₂₂ H ₂₃ N ₅	358.2032	358.2007	0.0025

7. Time course study



In an oven-dried, Ar-flushed vial with a stirring bar, a solution of 1-(2,2-difluorovinyl)-4-methylbenzene (**1**, 30 mg, 1 equiv) and 4-azidobenzonitrile (**2b**, 42 mg, 1.5 equiv) were dissolved in morpholine (0.3 mL, 0.4 M). The solution was stirred for 10 minutes at room temperature under Ar. Then, LiHMDS (78 μ L, 1 M in THF, 0.4 equiv) was added to the reaction mixture and it was purged with Ar three times. The reaction mixture was subjected to continuous stirring at a temperature of 75 °C. After 30 min, 1 h, 2 h, 4 h, 8 h, 16 h, 24 h, 32 h, and 48 h, 50 μ L aliquots of the reaction mixture were withdrawn using a syringe. The progress of the reaction was monitored by ¹⁹F NMR (Figure 3 in main text).

8. Mechanistic study





Figure S3. Aliquot ^{19}F NMR.




Figure S4. Crude ^{19}F NMR after work-up.

We also performed an energy minimization study using Chem3D to elucidate the conformation of the intermediate, **INT-1**. We found the *Z*-conformation (17.1988 kcal/mol) to be more stable than the *E*-geometry (24.9361 kcal/mol).

Z-conformation: 17.1988 kcal/mol




Figure S5. Energy minimization study of *Z*-conformation.

E-conformation: 24.9361 kcal/mol




Figure S6. Energy minimization study of *E*-conformation.

9. Regioisomer study:

The 3D structure of the 1,5-regioisomer (energy-minimized) reflecting the distance between the H_1 proton (labeled as yellow) and the protons in morpholine (H_a , H_a' and H_b , H_b') protons in morpholine:





Figure S7. 3D structure of 1,5-regioisomer

The 3D structure of the 1,4-regioisomer (energy-minimized) reflecting the distance between the H₁ proton (labeled as yellow) and the protons in morpholine (H_a, H_a' and H_b, H_b') protons in morpholine:






Figure S8. 3D structure of 1,4-regioisomer


10. Scale-up experiment:




In an oven-dried, Ar-flushed round-bottomed flask with a stirring bar, a solution of 1-(2,2-difluorovinyl)-4-methylbenzene (**1**, 154 mg, 1 equiv) and 4-azidobenzonitrile (**2b**, 108 mg, 0.75 equiv) were dissolved in morpholine (1.1 mL, 0.4 M). The solution was stirred for 10 minutes at room temperature under Ar. Then, lithium bis(trimethylsilyl)amide solution (0.4 mL, 1 M in THF, 0.4 equiv) was added to the reaction mixture and it was purged with Ar three times. The reaction mixture was stirred at 75 °C. After 16 h, another portion of 4-azidobenzonitrile (**2b**, 108 mg, 0.75 equiv) was dissolved in morpholine (1.1 mL, 0.4 molar) and added to the reaction mixture. The reaction was monitored by TLC under the same conditions. Upon completion after 90 h, brine was added and the organic layer was extracted with ethyl acetate ($\times 3$), dried with anhydrous Na_2SO_4 , and concentrated in vacuo. 4-(5-Morpholino-4-(*p*-tolyl)-1*H*-1,2,3-triazol-1-yl)benzonitrile was obtained in 57% yield after purification by column chromatography (gradient: 0–30% ethyl acetate in hexane).

11. ^1H , ^{19}F and ^{13}C NMR spectra:


^1H NMR of 3a




^{13}C NMR of 3a




¹H NMR of 3b




¹³C NMR of 3b



¹H NMR of 3c



¹³C NMR of 3c





¹H NMR of 3d

MD-002-004-C2-2.3.fid
70-91

7.93
7.91
7.90
7.88
7.85
7.83
7.78
7.76
- 7.26 CDCl₃

3.71
3.70
3.68

2.95
2.94
2.93



¹³C NMR of 3d



MD-002-004-C2.6.fid
SI C13

142.36
139.61
136.99
135.17
133.48
132.28
128.91
125.00
118.46
117.49
113.54
112.12


77.00 CDCl₃

66.56


50.47




¹H NMR of 3e




¹³C NMR of 3e




¹H NMR of 4a




¹³C NMR of 4a




¹H NMR of 4b




¹³C NMR of 4b



¹H NMR of 4c





¹⁹F NMR of 4c



¹³C NMR of 4c

TH-001-005-20.7.fid
C



163.68
161.69
141.34
138.67
138.16
137.78
137.70
130.64
130.57
129.03
128.69
127.94
120.20
120.18
116.24
115.90
112.20
112.00




¹H NMR of 4d

TH-001-005-01.3.fid
H 5-1 PRODUCT


7.609
7.609
7.517
7.517
7.505
7.505
7.326
7.286 CDCl₃



¹³C NMR of 4d





¹H NMR of 4e





¹⁹F NMR of 4e

TH-001-005-18.4.fid
F




¹³C NMR of 4e


TH-001-005-18.6.fid
C




¹H NMR of 4f




¹³C NMR of 4f



¹H NMR of 4g





¹³C NMR of 4g





¹H NMR of 4h

TH-001-005-25.3.fid
H




¹⁹F NMR of 4h


TH-001-005-25.3.fid
F




¹³C NMR of 4h




¹H NMR of 5a



¹³C NMR of 5a





¹H NMR of 5b



¹³C NMR of 5b

DM-SNAR-001.12(PUB).1.fid

- 143.88
- 140.10
- 138.90
- 138.01
- 133.20
- 129.19
- 127.93
- 127.83
- 125.06
- 117.92
- 112.67
- 77.00
- 54.08
- 29.51
- 27.62
- 21.32



12. References:

1. D. R. Strobach, *The Journal of Organic Chemistry*, 1971, **36**, 1438-1440.
2. V. G. Nenajdenko, G. N. Varseev, V. N. Korotchenko, A. V. Shastin and E. S. Balenkova, *Journal of Fluorine Chemistry*, 2003, **124**, 115-118.
3. S. A. Fuqua, W. G. Duncan and R. M. Silverstein, *The Journal of Organic Chemistry*, 1965, **30**, 1027-1029.
4. L. Yu, M.-L. Tang, C.-M. Si, Z. Meng, Y. Liang, J. Han and X. Sun, *Organic Letters*, 2018, **20**, 4579-4583.
5. K. Barral, A. D. Moorhouse and J. E. Moses, *Organic Letters*, 2007, **9**, 1809-1811.
6. S. Oekchuae, J. Sirirak, P. Charoensuksai, P. Wongprayoon, N. Chuaypen, J. Boonsombat, S. Ruchirawat, P. Tangkijvanich, A. Suksamrarn and P. Limpachayaporn, *Pharmaceuticals*, 2022, **15**, 504.
7. F. Pagliai, T. Pirali, E. Del Grosso, R. Di Brisco, G. C. Tron, G. Sorba and A. A. Genazzani, *Journal of Medicinal Chemistry*, 2006, **49**, 467-470.
8. Z.-C. Dai, Y.-F. Chen, M. Zhang, S.-K. Li, T.-T. Yang, L. Shen, J.-X. Wang, S.-S. Qian, H.-L. Zhu and Y.-H. Ye, *Organic & Biomolecular Chemistry*, 2015, **13**, 477-486.
9. M. Payne, A. L. Bottomley, A. Och, H. G. Hiscocks, A. P. Asmara, E. J. Harry and A. T. Ung, *Bioorganic & Medicinal Chemistry*, 2022, **57**, 116648.